関連する実験動画
Updated: Feb 20, 2026

07:51
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
Published on: August 1, 2025
1.1K
大麻の使用後の尿中の Δ9 - テトラヒドロカンナビノールおよび代謝産物濃度: 系統的なレビュー
Danielle McCartney1, Christopher Irwin2, Jonathon C Arnold3
1Sydney Pharmacy School, The University of Sydney, NSW, Australia.
Pharmacological research
|February 18, 2026
まとめ
大麻使用パターンは,尿薬検査結果に大きく影響します. 低用量および偶発的な使用は,職場での値を超えることができますが,大量使用者は,禁煙後数週間で陽性であることが判明します.
科学分野:
- 法医学毒理学 法医学毒理学
- 薬理学 薬理学とは
- カンナビノイド科学 カンナビノイド科学
背景:
- 尿中の薬物検査は,一般的に11-nor-9-carboxy-Δ9-tetrahydrocannabinol (11-COOH-THC) を検出することによって,大麻の使用を特定します.
- さまざまな当局は,陽性な検査結果のための異なる濃度値を実装しています.
- 大麻使用パターンが代謝産物濃度にどのように影響するかを理解することは,試験結果の解釈に極めて重要です.
研究 の 目的:
- 尿中の Δ9-テトラヒドロカンナビノール (THC) とその代謝産物濃度について,体系的に検討する.
- 異なる大麻投与と使用パターンがこれらの濃度に与える影響を分析する.
- 職場やスポーツで使用されている一般的な尿検査の基準値を文脈化します.
主な方法:
- 大麻の投与と使用者データを含む92件の適格な研究の体系的なレビュー.
- 尿中のTHCと11-COOH-THC濃度の合成,急性および繰り返し投与の研究から.
- 活発な使用および長期の禁酒期間中の濃度の分析.
主要な成果:
- THCの低単発または繰り返し投与,特に経口投与は,標準的な職場の値 (15ng/mL) を超える可能性があります.
- 毎週から毎日の大麻使用者は,禁断後の数週間,職場の値以上にとどまる可能性があります.
- 適度なTHC用量と週1回の使用は,WADAの決定制限値 (180ng/mL) を超えることができ,重量の使用者はより長く陽性であることが判明します.
結論:
- 大麻の使用パターンは,尿中の11-COOH-THC濃度に大きな影響を与えます.
- 現在の職場やスポーツでの試験の基準値は,低用量や偶発的な使用を含む様々な使用パターンによって超えられる可能性があります.
- 政策立案者や個人は,情報に基づいた値選択とリスク評価のために,この合成から利益を得ることができます.
関連する概念動画
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
810
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
810
Drug Concentrations: Measurements
1.2K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
1.2K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
945
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
945
Measurement of Bioavailability: Pharmacokinetic Methods
311
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
311
Therapeutic Drug Monitoring: Drug Analysis Methods
226
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
226
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
236
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
236

